GENE ONLINE|News &
Opinion
Blog

2021-11-08| Licensing

HitGen Ink Deal with Cambridge Molecular to Create a Deep Learning-Driven Drug Discovery Platform

by Daniel Ojeda
Share To

Discovering, synthesizing, and identifying hits in drug discovery is a time-consuming and expensive process. One method to speed up discovery is by using high throughput approaches such as large drug screens as DNA-encoded chemical libraries (DEL), fragment-based drug discovery (FBDD), and others. However, as the number of data increases, new approaches to analyzing the data and guiding the discovery process are necessary to reduce drug development time successfully.

More and more pharmaceutical companies are turning to Artificial Intelligence (AI), which has the ability to analyze large data sets, and it becomes better at recognizing patterns and making predictions. New types of AI, such as deep learning, go beyond that, they can take large amounts of raw data, decide what is important, and it improves over time as it learns from the outcome of its predictions.

These technologies have the potential to make drug development cheaper by accelerating the R&D phase. For this reason, in 2020, there was a record number of partnerships for AI-based drug discovery. 

With the goal of applying deep learning to DEL drug discovery, South Korea’s HitGen Inc. and UK-based Cambridge Molecular announced an exclusive alliance last week.

Related Article: Moderna Enters Gene Editing Market with Metagenomi Collaboration

 

DEL Libraries

HitGen has established a drug discovery platform with more than 1 trillion novel small molecules. Their main screening methods include DEL libraries, FBDD, and structured-based drug design. Their business model is diverse as it ranges from screening services for other companies to developing their own therapies. 

Their pipeline currently includes three products in clinical trials:

  1. HDAC inhibitor in trials for the treatment of multiple myeloma and solid tumors,
  2. 2nd generation NTRK/ROS1 inhibitor, and
  3. Immune-oncology agonist

Their latest collaboration with Cambridge Molecular focuses on their DEL libraries. DEL is a technique that uses DNA to tag small molecules. This makes it easier to identify the molecule that successfully binds the target protein.

Together they have created the DeepDELve 2 – Cambridge Molecular’s highly optimized DEL-specific deep learning system. According to the companies, this pipeline will provide a pathway to readily available potential ligands for drug targets. The DeepDELve2 is one of the most advanced systems currently deployed. No financial information about the deal was disclosed.

Related Article: Big Pharma and Non-Profits Join NIH, FDA in New Rare Diseases Drive

This collaboration follows last year’s acquisition of Vernalis Research, a leader in FBDD, from Ligand Pharmaceuticals for $25 million in cash and the collaboration with Evotec focusing on the development of anti-infectives.  

“We are pleased to take part in a paradigm shift in the DEL space with a partner as forward-thinking, determined, and effective as HitGen. A new capability with such an impact on the number and diversity of confirmed leads and on the speed of lead acquisition has the potential to transform the industry, enabling HitGen partners to access novel chemical space reliably and quickly, allowing faster iterations, and yielding more backup series. This is a once-in-a-generation opportunity,” said Dmitry Foxham, CEO of Cambridge Molecular.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
DeepMind’s AlphaFold Predicts Over 200 Million Protein Shapes in AI Breakthrough
2022-08-01
Boston’s Manifold Bio Secures $40M to Tackle Translational Obstacles
2022-07-15
Insilico Medicine Pinpoints New Targets for ALS With AI
2022-07-08
LATEST
Orna Therapeutics Secures Multi-Billion RNA Deal With Merck After $221 Million Series B
2022-08-17
FDA Allows Sales of Over-the-Counter Hearing Aids After Five Years of Consideration
2022-08-17
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
GSK’s Second Billion Dollar Acquisition Outprices their First of 2022
2022-08-16
Despite Global Acceptance, The UK Refuses to Buy AstraZeneca’s Evusheld, Citing ‘Insufficient Data’
2022-08-16
Antibody Treatment for Multiple Varieties of CoronaVirus
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-14
Bio Asia Pacific 2022
Tailand
2022-09-14
The Future of Health
Online
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!